RxDoctor Payments Data

Kestutis Aukstuolis, DO

Allergy & Immunology · Vienna, VANPI 1831400548

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi accounts for 72.5% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $11,933, more than ten times the $187 reported in 2019.

$17,251in general payments, 2019–2025

Across 237 payments — averaging $72.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$13K
  • AstraZeneca$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$442
  • Regeneron Healthcare Solutions, Inc.$436
  • GSK$313
  • CSL Behring$284
  • plus $2K from 21 others

What the payments were for

  • Consulting fees$9,98458%
  • Travel & lodging$3572%
  • Food & beverage$6,89040%
  • Education$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,251 in reported general payments places this provider in the 80th percentile of 133 allergy & immunology providers in Virginia.

See all allergy & immunology providers in Virginia

Medicare billing

Part B allowed, 2024
$178,687
Medicare patients
126
Services billed
4,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab15$62,252
Dupixent SyringeDupilumab15$54,595
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$21,726
Spiriva RespimatTiotropium Bromide16$10,175
Breo ElliptaFluticasone/Vilanterol17$7,953
Epinephrine17$5,839
DuleraMometasone/Formoterol11$5,495
Advair HfaFluticasone Propion/Salmeterol14$4,319
Qvar RedihalerBeclomethasone Dipropionate12$3,886
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$3,134
Cromolyn Sodium13$2,810
Albuterol Sulfate HfaAlbuterol Sulfate63$2,478
Azelastine Hcl84$2,370
Montelukast Sodium77$1,025
Fluticasone Propionate11$383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$313$29,67938 claims
Hikma Pharmaceuticals USAEpinephrine$30$5,83917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 133 allergy & immunology providers in Virginia.

Other allergy & immunology in Vienna

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →